Meet the New Frontrunners in the Race for a COVID-19 Vaccine

By Chris Lange Published Jul 1, 12:53PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Meet the New Frontrunners in the Race for a COVID-19 Vaccine — © MarianVejcik / Getty Images

Pfizer Inc. (NYSE: PFE | PFE Price Prediction) and BioNTech S.E. (NASDAQ: BNTX) advanced on Wednesday (in more ways than one) when they provided an update on their COVID-19 vaccine. These companies have been collaborating to produce a messenger RNA (mRNA) based vaccine for the past few months, and this work is yielding promising results.

Note that while this vaccine news is positive for these companies, a number of other coronavirus vaccine companies were taking a hit on Wednesday. While the race for a COVID-19 is of major importance to mankind, it will be incredibly lucrative for the first to cross the finish line.

In terms of the specifics for Pfizer and BioNTech’s announcement, preliminary U.S. data from the most advanced of four investigational vaccine candidates was released. These come from the BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic.

The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen. Basically, each vaccine encodes an optimized SARS-CoV-2 receptor binding domain (RBD) antigen, which prevents the spread and replication of the virus.

[nativounit]

Co-founder and CEO of BioNTech, Ugur Sahin, noted that, “These preliminary data are encouraging, showing that BNT162b1 which exploits RBD SARS-CoV-2 as a target antigen is able to produce neutralizing antibody responses in humans at or above the levels observed in convalescent sera.”

Looking ahead, the companies are seeking to progress to a large global Phase 2b/3 safety and efficacy trial, which may involve up to 30,000 healthy participants and is expected to begin in late July.

BioNTech stock traded up about 10% Wednesday to $73.33, in a 52-week range of $12.52 to $105.00. The consensus price target is $38.32.

Pfizer stock was up about 5%, at $34.35 in a 52-week range of $27.88 to $44.56. The consensus price target is $40.04.

[recirclink id=716417][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.